The new Express License service removes barriers to accessing this transformative gene editing technology for startups.  An Express License provides fast, simple and affordable access to the CRISPR/Cas9 patent portfolio through a non-exclusive internal research license.  DUBLIN, IRELAND and CHESHIRE, UK – 13th January 2025: ERS Genomics (‘ERS’), the.

  ERS Genomics stands as the global leader in CRISPR/Cas9 licensing, uniquely positioned at the intersection of cutting-edge science, commercial accessibility, and responsible innovation. Our approach to licensing, evidenced by over 145 licenses already granted worldwide, proves that sophisticated IP management can accelerate rather than hinder scientific progress and support.

ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement License agreement provides Université de Montréal access to CRISPR gene editing technology for use across its platform services   Dublin, Ireland, and Montreal, Canada, 01 October 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Université de Montréal (‘UdeM’),.